Biomarkers in oncology drug development: rescuers or troublemakers?
作者： Estelle Marrer , Frank Dieterle
DOI: 10.1517/17425255.4.11.1391
关键词:
摘要: Oncology is considered as the pioneer indication for clinical application of molecular biomarkers. Newly developed targeted anticancer therapies call implementation biomarker strategies but even novel cytotoxic treatments use biomarkers assessment efficacy and toxicity. Biomarkers may play several roles in progression a drug from research to personalised medicine. In particular are used understand mechanism action drug, monitor modulation intended target, assess safety, adapt dosing schedule, select patients prognosticate outcome. Nowadays, oncology still challenged only limited number drugs on market have companion test be mandatorily performed before treatment. This contradiction with current major investment pharmaceutical sector devoting identification development. What measurable milestones outcomes these investments? How does development contribute reaching ultimate goal finding right molecules targets at doses schedules patients? review provides critical overview recent salient achievements
novartis.com参考文章(35)
Hagop M Kantarjian, Jorge E Cortes, BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices. Journal of The National Comprehensive Cancer Network. ,vol. 6, ,(2008)
Jose de Leon, Margaret T. Susce, Elaina Murray-Carmichael, The AmpliChip™ CYP450 Genotyping Test Molecular Diagnosis & Therapy. ,vol. 10, pp. 135- 151 ,(2006) , 10.1007/BF03256453
Neil P Shah, Advanced CML: therapeutic options for patients in accelerated and blast phases. Journal of The National Comprehensive Cancer Network. ,(2008)
Olivier Grenet, Frank Dieterle, Jacky Vonderscher, Estelle Marrer, Andre Cordier, Eiko Suzuki, Monitoring kidney safety in drug development: emerging technologies and their implications. Current Opinion in Drug Discovery & Development. ,vol. 11, pp. 60- 71 ,(2008)
Brian J. Druker, Imatinib as a paradigm of targeted therapies. Advances in Cancer Research. ,vol. 91, pp. 1- 30 ,(2004) , 10.1016/S0065-230X(04)91001-9
József Tímár, István Láng, None, Az epidermális növekedési faktor receptorát célzó terápiák RAS paradoxona vastag- és végbélrákban Magyar onkologia. ,vol. 52, pp. 185- 191 ,(2008) , 10.1556/MONKOL.52.2008.2.7
Ismail Kola, John Landis, Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery. ,vol. 3, pp. 711- 716 ,(2004) , 10.1038/NRD1470
Sreenath V. Sharma, Daphne W. Bell, Jeffrey Settleman, Daniel A. Haber, Epidermal growth factor receptor mutations in lung cancer Nature Reviews Cancer. ,vol. 7, pp. 169- 181 ,(2007) , 10.1038/NRC2088
Torsten Haferlach, Ulrike Bacher, Wolfgang Kern, Susanne Schnittger, Claudia Haferlach, Diagnostic pathways in acute leukemias: a proposal for a multimodal approach. Annals of Hematology. ,vol. 86, pp. 311- 327 ,(2007) , 10.1007/S00277-007-0253-2
Zheng Yang, Amy Camuso, Richard Smykla, Kelly McGlinchey, Krista Fager, Christine Flefleh, Stephen Castaneda, Ivan Inigo, David Kan, Mei-Li Wen, Robert Kramer, Anne Blackwood-Chirchir, Francis Y. Lee, Feng R. Luo, Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure Clinical Cancer Research. ,vol. 12, pp. 7180- 7186 ,(2006) , 10.1158/1078-0432.CCR-06-1112